UNSPSC 51294503: Brofaromine

This classification denotes a monoamine oxidase inhibitor with the molecular formula C14H16BrNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WV4B8Q07H, chemically known as piperidine, 4-(7-bromo-5-methoxy-2-benzofuranyl)-, hydrochloride but generally known as brofaromine, which bears US NIH Compound Identifier 44571. Brofaromine most often comes in base and hydrochloride forms. European Medicines Agency schedules Brofaromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05899MIG.

UNSPSC 51294503 Brofaromine is a Commodity code covering pharmaceutical products, but the recent state and local activity under this code shows little direct alignment with brofaromine itself. Instead, the solicitations tagged to this code reflect broader pharmaceutical procurement — notably naloxone (an opioid antagonist), generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program planning. State and local buyers pursuing these opportunities include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating members). The work spans supply and distribution of specific drug products, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and establishment of wholesale distribution channels through authorized vendors.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, where vendors must cover all shipping and delivery costs and maintain specific insurance coverage including professional liability. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating jurisdictions, requiring vendors to maintain relationships with at least two of three authorized wholesalers, achieve cGMP and DSCSA compliance, and accept a 3 percent administrative fee on all purchases. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) as preliminary market intelligence gathering for a direct-to-manufacturer prescription program, indicating upstream procurement planning but no immediate contract awards.